Research projects
Childhood Cancer Immunotherapy Program
New Childhood Brain Cancer Research
37 Years of Dedication
Introducing the Telethon Kids Cancer Centre
Unlocking the key to leukaemia progression in kids
The new sarcoma research team
Meet Finlay
The SJ Elliot Cancer Trial
Latest publications
ONC201 in Combination with Paxalisib for the Treatment of H3K27-Altered Diffuse Midline Glioma
Diffuse midline gliomas (DMG), including diffuse intrinsic pontine gliomas (DIPG), are the most lethal of childhood cancers. Palliative radiotherapy is the only established treatment, with median patient survival of 9 to 11 months. ONC201 is a DRD2 antagonist and ClpP agonist that has shown preclinical and emerging clinical efficacy in DMG.
Children's Cancers Published research Brain Tumour ResearchPharmacokinetics of PEGasparaginase in Infants with Acute Lymphoblastic Leukemia
PEGasparaginase is known to be a critical drug for treating pediatric acute lymphoblastic leukemia (ALL), however, there is insufficient evidence to determine the optimal dose for infants who are less than one year of age at diagnosis. This international study was conducted to identify the pharmacokinetics of PEGasparaginase in infants with newly diagnosed ALL and gather insight into the clearance and dosing of this population.
Children's Cancers Published research Early Childhood Development Leukaemia Translational ResearchPI3K/mTOR is a therapeutically targetable genetic dependency in diffuse intrinsic pontine glioma
Diffuse midline glioma (DMG), including tumors diagnosed in the brainstem (diffuse intrinsic pontine glioma; DIPG), are uniformly fatal brain tumors that lack effective treatment.
Children's Cancers Published research Brain Tumour Research